

Special Issue

Recent Scientific Advancements towards a Vaccine against Group A Streptococcus

Message from the Guest Editors

Group A Streptococcus (GAS) is a major global pathogen, disproportionately affecting low- and middle-income countries, particularly through autoimmune sequelae such as acute rheumatic fever and rheumatic heart disease (RHD). The World Health Organization has highlighted the need for a GAS vaccine, with a particular focus on reducing the burden of pharyngitis as a precursor to the prevention of RHD. The focus of this Special Issue is to bring together exciting developments and considerations for vaccine development against GAS, including epidemiological justification for vaccination or support for particular antigens. We invite you to submit your original research, reports or reviews towards the progression of a vaccine against GAS. Topics can include, but are not limited to, the following: (i) candidate antigens, (ii) correlates of protection, (iii) novel delivery methods, (iv) mucosal immunity, (v) field studies of natural infections, (vi) assay development, and (vii) infection models. Dr. Helen Alexandra Shaw

Guest Editors

Dr. Helen Alexandra Shaw
The Medicines and Healthcare Regulatory Agency (MHRA), London, UK
Dr. Helge C. Dorfmueller
School of Life Sciences, University of Dundee, Dundee, Scotland, UK

Deadline for manuscript submissions

closed (20 March 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/135098

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).